Recent Press Releases

ICON Reports Third Quarter 2014 and Increases Earnings Guidance

Net revenue increased 14.1% year on year to $388 million. Income from operations was $59.4 million or 15.3% of revenue. Earnings per share were 79 cents. Gross business wins were $504...

FDA Approves Baxter's OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A

DEERFIELD, Ill.--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine...

FDA approves new treatment for rare form of hemophilia

The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A...

Five Prime Therapeutics Announces Expansion of Respiratory Disease Research Collaboration and License Agreement With GSK

SOUTH SAN FRANCISCO, Calif. -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), today announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to...

Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer

Friday, 24 October 2014 AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...

aTyr Pharma Inc. Appoints John C. McKew, Ph.D., As Vice President, Research

SAN DIEGO and HONG KONG, Oct. 22, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative rare disease therapeutics enterprise, announced today that rare disease expert John C. McKew,...

ProNAi Therapeutics, Inc. Strengthens Senior Management Team To Advance DNAi®-based Oncology Therapeutics

VANCOUVER, BC and PLYMOUTH, MI, Oct. 22, 2014 /PRNewswire/ - ProNAi Therapeutics Inc., a private company dedicated to developing and commercializing a new class of therapies based on its proprietary...

Therapix Names Jan Turek CEO

Therapix Biosciences Names Jan Turek CEO TEL AVIV, Israel, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Therapix Bio (TRPX.TA) (THXBY) today announced that Jan Turek has been named Chief Executive Officer,...

BaseHealth Names Former Illumina, Inc. (ILMN) Executive Jorge Velarde As New CEO and President

Former Vice President of Business Development at Illumina brings vision and expertise to BaseHealth as company expands into new commercial markets. Redwood City, CA (PRWEB) October 20, 2014...

Aesica Appoints VP, Business Development And Business Development Director For Finished Dose To Drive Service In Europe And Achieve Further Growth

20th October 2014: Aesica, the global contract development and manufacturing organisation (CDMO), today announced the appointment of two senior business development positions. Detlef Behrens has been...

Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer

Industry Veteran to Lead Business Development and Commercialization MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative...

Revalesio Names Bert van den Bergh President

Revalesio Corporation strengthened its executive leadership with the appointment of Bert van den Bergh as President. Mr. van den Bergh brings extensive industry experience to Revalesio as the company...

23andMe, Inc. Appoints Ruby Gadelrab Vice President Of Commercial Marketing

MOUNTAIN VIEW, Calif., Oct. 20, 2014 /PRNewswire/ -- 23andMe, the leading personal genetics company, today announced the appointment of Ruby Gadelrab as vice president, commercial marketing. Gadelrab...

Zola P. Horovitz To Retire From GenVec Inc. (GNVC) Board

GAITHERSBURG, Md., Oct. 20, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014....

Epic Sciences Appoints Michael Giske As Chief Information Officer

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Epic Sciences announced today the appointment of Michael Giskeas chief information officer. Mr. Giske has more than 25 years of defining, designing and...

Amgen (AMGN) Announces Appointment Of R. Sanders Williams To Board Of Directors

THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W....

Advaxis, Inc. Appoints David J. Mauro, M.D., Ph.D., As Chief Medical Officer

PRINCETON, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David...

Karus Therapeutics Appoints New Head Of Clinical Development And Head Of Biology

Oxford, UK – 21 October 2014 – Karus Therapeutics ('Karus'), a leader in the development of innovative medicines for the treatment of inflammatory diseases and cancer, today announced...

Cytori Therapeutics, Inc. Announces Resignation of Lloyd H. Dean Effective November 1, 2014

SAN DIEGO--(BUSINESS WIRE)--The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H. Dean has tendered his resignation as a member of the Board, effective...

Apollo Medical Holdings Appoints David M. Badour As Senior Vice President Of Business Development

GLENDALE, Calif., Oct. 21, 2014 /PRNewswire/ -- Apollo Medical Holdings, Inc. (ApolloMed) (OTC-QB: AMEH), an integrated physician-centric healthcare delivery company, today announced the appointment...